Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia

Niparuck, Pimjai; Limsuwanachot, Nittaya; Pukiat, Sulada; Chantrathammachart, Pichika; Rerkamnuaychoke, Budsaba; Magmuang, Sutada; Phusanti, Sithakom; Boonyawat, Kochawan; Puavilai, Teeraya; Angchaisuksiri, Pantep; Ungkanont, Artit; Chuncharunee, Suporn

doi:10.1186/s40164-019-0127-z

Table 2 Factors affecting relapse free and overall survival in 141 non-transplant AML patients

From: Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia

Factors	Overall study population				Completed consolidation therapy				AML with normal karyotype				AML with normal karyotype and completed consolidation therapy				Supportive care
Factors	mRFS (Mo) N = 73	p	mOS (Mo) N = 141	p	mRFS (Mo) N = 41	p	mOS (Mo) N = 41	p	mRFS (Mo) N = 42	p	mOS (Mo) N = 83	p	mRFS (Mo) N = 22	p	mOS (Mo) N = 23	p	mOS (Mo) N = 30	p
Age (years)
< 60	11	0.235	13	0.007	14	0.196	30	0.436	12	0.734	17	0.003	18	0.504	31	0.957	3	0.781
≥ 60	22	0.235	4	0.007	NR	0.196	NR	0.436	22	0.734	4	0.003	NR	0.504	NR	0.957	2	0.781
White blood cell count
< 100,000/μL	12	0.004	11	0.007	48	0.074	33	0.013	18	0.003	15	0.008	48	0.029	63	0.017	2	0.12
> 100,000/μL	6	0.004	7	0.007	14	0.074	17	0.013	6	0.003	5	0.008	6	0.029	23	0.017	1	0.12
Cytogenetic risk
Favorable	14	0.141	18	0.000	14	0.044	25	0.007	–	–	–	–	–	–	–	–	–	0.236
Intermediate	12		11		22		31										3
Unfavorable	9		4		9		14										2
Gene mutation
FLT3-ITD+	2	0.047	9	0.047	15	0.518	16	0.402	1	0.000	7	0.051	–	0.156	–	0.397	1	0.072
NPM1+	18		15		51		63		18		15		51		63		2
FLT3-ITD+ and NPM1+	4		5		22		23		4		5		22		23		1
CEBPA+	17		22		NR		23		17		22		NR		23		16
No mutation	10		7		14		30		11		9		11		31		2
FLT3-ITD mutation
Yes	5	0.04	7	0.076	15	0.686	16	0.131	1	0.000	7	0.074	–	–	–	–	1	0.416
No	12	0.04	9	0.076	18	0.686	31	0.131	13	0.000	13	0.074	22		31		2	0.416
NPM1 mutation
Yes	18	0.16	15	0.178	51	0.146	63	0.222	18	0.115	15	0.27	51	0.061	63	0.161	1	0.665
No	11	0.16	9	0.178	14	0.146	30	0.222	12	0.115	11	0.27	14	0.061	31	0.161	2	0.665
CEBPA mutation
Yes	13	0.439	19	0.149	NR	0.411	23	0.834	17	0.417	19	0.362	NR	0.601	23	0.547	16	0.016
No	11	0.439	9	0.149	14	0.411	31	0.834	12	0.417	11	0.362	22	0.601	33	0.547	2	0.016
Consolidation regimen
HiDAC	12	0.257	31	0.535	1	0.529	31	0.208	12	0.188	31	0.273	12	0.203	31	0.281		–
IDAC	14		25		14		25		22		31		22		31
Azacitidine	NR		NR		NR		NR		NR		NR		NR		NR
Consolidation regimen
HiDAC	12	0.683	31	0.803	12	0.788	31	0.557	12	0.25	31	0.267	12	0.226	31	0.267		–
IDAC	14	0.683	25	0.803	14	0.788	25	0.557	22	0.25	31	0.267	22	0.226	31	0.267		–
Complete remission (CR)
CR		–	17	0.000		–		–	–	–	23	0.005	–	–	–	–		–
No CR		–	6	0.000		–		–	–	–	9	0.005	–	–	–	–		–

mRFS median relapse free survival, mOS median overall survival, NR not reach, NA not available

Back to article page

ISSN: 2162-3619

Contact us

Submission enquiries: journalsubmissions@springernature.com

Experimental Hematology & Oncology

Contact us